XENE

Xenon Pharmaceuticals Inc. XENE

NasdaqMid CapHealthcare

13F Pro quality score

Rank #2,804 of 3,064

Why it scores 24Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$0

Quarter to Jun 30

Net income

$-110.74M

Quarter to Jun 30

Free cash flow

$-95.67M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$6.09B total
FMR LLC
$582.35M-10.8%
BlackRock, Inc.
$454.06M+33.4%
Avoro Capital Advisors LLC
$348.75M0.0%
Polar Capital Holdings Plc
$275.88M+3.8%
DRIEHAUS CAPITAL MANAGEMENT LLC
$266.70M-1.6%
Jupiter Topco LLC
$252.67M--
PRICE T ROWE ASSOCIATES INC /MD/
$196.06M+144.3%
JPMORGAN CHASE & CO
$157.38M+36.1%
Capital International Investors
$142.55M-11.7%
T. Rowe Price Investment Management, Inc.
$130.90M+127.8%
STATE STREET CORP
$118.89M+14.5%
TWO SIGMA INVESTMENTS, LP
$99.16M+171.1%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$97.52M0.0%
Affinity Asset Advisors, LLC
$96.27M-4.8%
WESTFIELD CAPITAL MANAGEMENT CO LP
$90.98M+7.5%
ALLIANCEBERNSTEIN L.P.
$90.85M+11.3%
FRANKLIN RESOURCES INC
$86.78M+12.3%
WELLINGTON MANAGEMENT GROUP LLP
$86.04M-70.5%
CITADEL ADVISORS LLC
$84.58M-47.2%
GEODE CAPITAL MANAGEMENT, LLC
$82.69M+25.4%
Siren, L.L.C.
$79.59M0.0%
BNP Paribas Asset Management Holding S.A.
$77.91M-3.8%
Pictet Asset Management Holding SA
$71.65M+74.7%
BRAIDWELL LP
$68.29M-15.5%
Nuveen, LLC
$59.95M+297.2%
See all 317 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/XENE

Earnings Per Share

13fpro.ai/company/XENE

Loading ratio trend…

XENE key financials by period

Reported revenue, net income and operating margin by fiscal year, from Xenon Pharmaceuticals Inc.'s annual filings on SEC EDGAR.

Xenon Pharmaceuticals Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$7.5M$-345.9M—
FY 2022$9.4M$-125.4M—
FY 2021$18.4M$-78.9M—
FY 2020$32.2M$-28.8M-97.3%
FY 2019$6.8M$-41.6M—
FY 2017$311.0K$-30.7M—
Source: XENE filings on SEC EDGAR →

XENE insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Xenon Pharmaceuticals Inc. (XENE): stock profile, AI score and financials

Xenon Pharmaceuticals Inc. (XENE) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores XENE at 24.0/100 on a composite quality score built from its SEC filings, placing it at rank #2,804 of 3,064 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (2.3) and institutional flow (16.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Xenon Pharmaceuticals Inc. reports net income of $-110.7M, free cash flow of $-95.7M. Top institutional holders of XENE by reported 13-F value include FMR, BlackRock, Avoro Capital Advisors, based on the most recent SEC filings. XENE trades on the Nasdaq exchange and files with the SEC under CIK 1582313. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate XENE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Xenon Pharmaceuticals Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1582313 →